On July 9th, 2024, the U.S. FDA approved Arcutis Biotherapeutics’ ZORYVE® (roflumilast) for treating atopic dermatitis (AD), the most common type of eczema affecting millions in the U.S. This once-daily, steroid-free cream could become a new standard of care for AD.
Long COVID Immune Profiles Appear Largely Normal
Spinal fluid immune profiles were largely normal in people with neurologic long COVID symptoms in a case-control study, suggesting brain inflammation was not a cause
November 15, 2023